Cargando…

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma

BACKGROUND: The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP) has significantly improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL). However, new predictors of patient response to R-CHOP have not been e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Geundoo, Yoon, Dok Hyun, Kim, Shin, Lee, Dae Ho, Lee, Sang-wook, Huh, Jooryung, Suh, Cheolwon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128890/ https://www.ncbi.nlm.nih.gov/pubmed/21747882 http://dx.doi.org/10.5045/kjh.2011.46.2.103

Ejemplares similares

Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement
por: Ko, Ock Bae, et al.
Publicado: (2008)

A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy
por: Kim, Kyung Min, et al.
Publicado: (2009)

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
por: Yoo, Changhoon, et al.
Publicado: (2010)

A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
por: Hwang, Hee Sang, et al.
Publicado: (2021)

EBV-positive diffuse large B-cell lymphoma of the elderly with aberrant expression of CD3 and TIA-1
por: Lee, Miji, et al.
Publicado: (2013)

Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems
por: Hwang, Hee Sang, et al.
Publicado: (2014)

Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma
por: Hwang, Hee Sang, et al.
Publicado: (2013)

Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma
por: Choi, Eun-Ji, et al.
Publicado: (2017)

Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy
por: Oh, Sukjoong, et al.
Publicado: (2011)

Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient
por: Choi, Eunji, et al.
Publicado: (2015)

Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
por: Jo, Jungmin, et al.
Publicado: (2014)

Modified Stage Grouping of Diffuse Large B-Cell Lymphoma Involving the Same Side of the Diaphragm in the Rituximab Era
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience
por: Kim, Jeongseok, et al.
Publicado: (2014)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma
por: Jo, Jae-Cheol, et al.
Publicado: (2012)

Rituximab-CHOP Induced Interstitial Pneumonitis in Patients with Disseminated Extranodal Marginal Zone B Cell Lymphoma
por: Kim, Kwang Min, et al.
Publicado: (2008)

Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients
por: Jeong, Jae Ho, et al.
Publicado: (2017)

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)
por: Yoon, Dok Hyun, et al.
Publicado: (2017)

Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology
por: Ahn, Yongchel, et al.
Publicado: (2017)

Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Cho, Min-Chul, et al.
Publicado: (2018)

CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma
por: Koh, Young Wha, et al.
Publicado: (2014)

Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis
por: Huh, Jin-Young, et al.
Publicado: (2017)

Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Shim, Hyoeun, et al.
Publicado: (2019)

Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis
por: Hong, Junshik, et al.
Publicado: (2010)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
por: Koh, Young Wha, et al.
Publicado: (2017)

Primary mediastinal large B-cell lymphoma: a single-center experience in Korea
por: Ahn, Heui June, et al.
Publicado: (2014)

P1186: RETROSPECTIVE STUDY: ZANUBRUTINIB COMBINED WITH R-CHOP OR R-CHOP REGIMEN IN THE TREATMENT OF UNTREATED NON-GERMINAL CENTER B-CELL SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA WITH EXTRANODAL INVOLVEMENT.
por: Caixia, LI, et al.
Publicado: (2023)

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
por: Wei, Xiaolei, et al.
Publicado: (2014)

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma
por: Kim, Jeong Eun, et al.
Publicado: (2012)

A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma: Incorporation of Serum β-2 Microglobulin to PINK
por: Kang, Sora, et al.
Publicado: (2023)

Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience
por: Seo, Seyoung, et al.
Publicado: (2014)

Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution
por: Kim, Meejeong, et al.
Publicado: (2021)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era
por: Kang, Jihoon, et al.
Publicado: (2017)

Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
por: Hu, Xin, et al.
Publicado: (2017)

Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma
por: Ha, Joo Young, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ete6ogtopr9rc4gutnia370jh3